DataMeds AI (MEDS) shares fell 11% to settle at $3.11 Monday after the company launched Health Lives Here, a mobile platform developed with Tollo Health and the NFL Alumni Association. The app initially serves people using GLP-1 receptor agonists through telemedicine consultations, direct-to-home pharmacy fulfillment via DataMeds’ Corexa Health subsidiary, nutritional support products and an AI health coach. It integrates data from devices including Apple Watch and Oura Ring. The platform is distributed through NFL Alumni Health and initially includes Moose Pharmacy of Concord in North Carolina, with users able to access credentialed physicians, GLP-1 therapy evaluations, cash-payment options for brand-name GLP-1 drugs, home delivery or prescription transfers to local pharmacies, and Tollo Health’s nonprescription Forzet medical food for muscle degradation associated with weight-loss therapies. DataMeds plans to expand the service to Long COVID patients in the fourth quarter of 2026 and later to oncology patients, supported by diagnostic laboratory services under development through its acquisition of Helomics Corporation. The company also aims to add digital twin capabilities and a proprietary blockchain option by 2027. A separate market update reported MEDS up 31.83% at $4.10 at publication, leaving a discrepancy in reported Monday price action.